Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening

Yonsei Medical Journal

Volumn 50, Issue 3, 2009, Pages 331-334

  An, Sung Whan ^a,b   Kim, Nam Kyu ^a   Chung, Hyun Cheol ^a,c  

^a Yonsei University College of Medicine   (South Korea)

^b Genomictree Inc   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Colorectal cancer screening; Genetic and epigenetic alterations; Stool DNA

Indexed keywords

APC PROTEIN; DNA MARKER; GENOMIC DNA; K RAS PROTEIN; PLACENTA PROTEIN 5; PROTEIN BAT 26; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 2; UNCLASSIFIED DRUG; VIMENTIN;

ADENOMA; CANCER SCREENING; CHROMOSOME 12; CHROMOSOME 17P; CHROMOSOME 5Q; COLON POLYPOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA DEGRADATION; DNA FRAGMENTATION; DNA INTEGRATION; DNA METHYLATION; EPIGENETICS; FECES ANALYSIS; GENETIC ANALYSIS; GENETIC MARKER; GENETIC STABILITY; HUMAN; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; REVIEW; SENSITIVITY AND SPECIFICITY; STOOL DNA TEST; TUMOR SUPPRESSOR GENE;

COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; FECES; GENETIC MARKERS; TUMOR MARKERS, BIOLOGICAL;

EID: 67651156046     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.3.331     Document Type: Review

References (32)

1. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
4. Eastwood M. Diet and intestinal disease. Compr Ther 1977;3:19-23.
5. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058-65.
6. Mak T, Lalloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. Br J Surg 2004;91:790-800.
7. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Piercall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
9. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007;5:111-7
10. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008;135:489-98.
11. Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009;136:459-70.
12. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004;126:1270-9.
13. Baylin SB. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 2002;12:331-7.
14. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
15. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
16. Issa JP. The epigenetics of colorectal cancer. Ann N Y Acad Sci 2000;910:140-53; discussion 153-5.
17. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-5.
18. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008;14:524-31.
19. Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 2007;52:2287-91.
20. Oberwalder M, Wonter C, Wöntner C, Fiegl H, Goebel G, Zitt M. et al. SFRP2 methylation in fecal DNA - a marker for colorectal polyps. Int J Colorectal Dis 2008;23:15-9.
21. Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum 2007;50:1618-26; discussion 1626-7.
22. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005;97:1124-32.
23. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 2005;14:183-91.
24. Whitney D, Skoletsky J, Moore K, Boynton K, Kann L, Brand R, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004;6:386-95.
25. Anti M, Armuzzi A, Morini S, Iascone E, Pignataro G, Coco C, et al. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 2001;48:238-46.
26. Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in Stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69:4691-9.
27. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007; 45:1129-38.
28. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, et al. Epigenetic inactivation of TPFI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850-8.
29. Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007;121:301-7.
30. Rollin J, Iochmann S, Bléchet C, Hubé F, Régina S, Guyétant S, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005; 92:775-83.
31. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3:e486.
32. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:114-23.